These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 37738842)

  • 41. Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma.
    Zheng Y; Liu L; Wang Y; Xiao S; Mai R; Zhu Z; Cao Y
    Cell Biosci; 2021 Mar; 11(1):63. PubMed ID: 33789726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
    Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
    Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
    Choi IK; Li Y; Oh E; Kim J; Yun CO
    PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
    Pakola S; Quixabeira DCA; Kudling TV; Clubb JHA; Grönberg-Vähä-Koskela S; Basnet S; Jirovec E; Arias V; Haybout L; Heiniö C; Santos JM; Cervera-Carrascon V; Havunen R; Anttila M; Hemminki A
    Front Immunol; 2023; 14():1171083. PubMed ID: 37475863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis.
    Wei X; Liu L; Wang G; Li W; Xu K; Qi H; Liu H; Shen J; Li Z; Shao J
    Oncol Rep; 2015 Jan; 33(1):111-8. PubMed ID: 25339149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
    Liu X; Li Z; Sun J; Zhang Z; Li W
    BMC Cancer; 2023 Mar; 23(1):259. PubMed ID: 36941554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
    Hoffmann D; Wildner O
    Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
    Wang Y; Zhang X; Xu C; Nan Y; Fan J; Zeng X; Kwon BS; Ju D
    Front Immunol; 2022; 13():1004475. PubMed ID: 36544785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
    Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
    Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor.
    Zhang Y; Wu J; Zhang H; Wei J; Wu J
    Front Bioeng Biotechnol; 2020; 8():574007. PubMed ID: 33042975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Passaro C; Alayo Q; De Laura I; McNulty J; Grauwet K; Ito H; Bhaskaran V; Mineo M; Lawler SE; Shah K; Speranza MC; Goins W; McLaughlin E; Fernandez S; Reardon DA; Freeman GJ; Chiocca EA; Nakashima H
    Clin Cancer Res; 2019 Jan; 25(1):290-299. PubMed ID: 30279232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models.
    Liu W; Wang X; Feng X; Yu J; Liu X; Jia X; Zhang H; Wu H; Wang C; Wu J; Yu B; Yu X
    Cancer Lett; 2022 Jun; 535():215661. PubMed ID: 35325845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
    McKenna MK; Englisch A; Brenner B; Smith T; Hoyos V; Suzuki M; Brenner MK
    Mol Ther; 2021 May; 29(5):1808-1820. PubMed ID: 33571680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma.
    Fang L; Tian W; Zhang C; Wang X; Li W; Zhang Q; Zhang Y; Zheng J
    Pharmacol Res; 2023 Mar; 189():106701. PubMed ID: 36796464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.